Mewburn Ellis hires in Munich
European patent attorney Dr. Thomas Wolter has joined the Munich office of European IP law firm Mewburn Ellis.
He brings 25 years’ experience gained across a range of proceedings before the European Patent Office, the German Federal Patent Court, the German Federal Court of Justice and the national civil courts in oppositions, nullity actions, and infringement suits.
“Wolter’s arrival sends a very clear signal that no other IP firm is better positioned to support Europe’s research and innovation community in their EP patent strategies and wider IP needs,” said Tanis Keirstead, Munich partner, Mewburn Ellis.
Wolter has particular technical expertise in complex patents relating to therapeutic antibodies, human blood plasma products, and the production and formulation of biologics, said a Mewburn Ellis statement.
“I am delighted to join Mewburn Ellis,” said Wolter. “The firm has a long-standing reputation for excellence and I look forward to helping propel new growth for the firm here in Germany, across Europe, and globally.”
Wolter spent almost 25 years at Reitstötter Kinzebach as a patent attorney and partner, before leaving in January 2020.
Mewburn Ellis opened its Munich office in November 2017, and began offering a full range of patent, trade mark and design services, including drafting, prosecution, oppositions, litigation, IP strategy consulting and portfolio management.
In April 2019, Mewburn Ellis announced the promotion of three of its attorneys to partnership and three to its new ‘director’ role.
Two patent attorneys, Sarah Kostiuk-Smith and Eliot Ward, were named partners. Jacqueline Pang, a trademark attorney, was also promoted to the partnership.
Sofia Arenal, a trademark attorney, took up the role of trademark director. Patent attorneys Elizabeth Dale and Rhiannon Wescott became the firm’s newest patent directors. Dale is a member of the firm’s chemistry practice group. Wescott, who joined the firm in 2011, predominantly works in the biotechnology, protein engineering and antibody technology sectors.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
